Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

Inclusion Criteria:

1. Subject voluntarily takes part in the study after being fully informed,signs awritten ICF, and agrees to follow procedures specified in the study protocol;

2. Subject who meets one of the following criteria: i. History of gout attack: Meeting 2015 ACR/EULAR Gout Classification Criteria andfasting serum uric acid ≥ 480 μmol/L at screening (local laboratory of study site)ii. For asymptomatic hyperuricemia, it is acceptable to meet either of the twocriteria:

3. Serum uric acid ≥ 420 μmol/L for at least 3 months (subject to hospital medicalrecord or test report), diagnosis with hyperuricemia before screening, andfasting serum uric acid at screening ≥ 540 μmol/L (local laboratory of studysite);

4. Serum uric acid ≥ 420 μmol/L for at least 3 months (subject to hospital medicalrecord or test report), diagnosis with hyperuricemia before screening, andfasting serum uric acid at screening ≥ 480 μmol/L (local laboratory of studysite), with concomitant primary hypertension or primary hyperlipidemia or type 2 diabetes mellitus, which is treated with a stable dose of antihypertensive orlipid-lowering or hypoglycemic treatment for at least 3 months;

5. At screening, 18.0 kg/m2 ≤ body mass index (BMI) ≤ 32.0 kg/m2;

6. Hematology, Blood chemistry and Urinalysis examination were basically normal.

Exclusion Criteria:

1. Prior intolerance to benzbromarone or contraindication to medication;

2. Secondary hyperuricemia caused by tumor, chronic kidney disease, blood disease ordrugs, etc.;

3. Arthropathy caused by arthritis rheumatoid, purulent arthritis, traumatic arthritis,psoriatic arthritis, pseudogout or systemic lupus erythematosus, etc.;

4. Arthropathy caused by chemotherapy, radiotherapy or chronic lead poisoning;

5. Urinary calculi confirmed by B-ultrasound during screening period;